Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2025 interim financial results and provided corporate updates.
FINANCIAL HIGHLIGHTS
As of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representing an increase of approximately 49% compared to 2024, driven mainly by pharmaceutical sales. In particular, the domestic sales revenue of our core product, TUOYI® (toripalimab), reached approximately RMB954 million, an increase of approximately 42% from 2024.
Total research and development ("R&D") expenses of the company were approximately RMB745 million for the first half of 2025, an approximately 36% increase compared to 2024. The higher R&D expenses were mainly due to the company's focus on more competitive and innovative R&D pipelines and accelerated clinical development during the first half of 2024.
Loss attributable to owners of the company fell to RMB413 million, representing a decrease of approximately RMB232 million or approximately 36% compared to 2024.
During the first half of 2025, net cash inflow from financing activities was approximately RMB1,386 million, primarily attributable to the successful placement of the company's new H shares on June 20, 2025, which generated a net inflow of approximately RMB940 million. This net cash inflow fully offset the cash outflows from operating and investing activities, leading to an overall increase in bank balances and cash.
As of June 30, 2025, the aggregate balance of bank balances and cash and financial products of the company was approximately RMB3,490 million, ensuring a relatively stable liquidity position to support the company's continued development.
BUSINESS HIGHLIGHTS
During the first half of 2025, we focused on addressing "unmet medical needs". We have made original, innovative and breakthrough progress in the discovery, R&D and commercialization of innovative therapies and novel drugs with accelerating international development. The following are achievements and milestones we have reached:
Advancements in the pipeline: the company's innovative R&D field has expanded from monoclonal antibodies to the research and development of various drug modalities, including small molecules drugs, antibody drug conjugates ("ADC"), bi-specific or multi-specific antibodies, fusion protein, nucleic acid drugs and vaccines, as well as the exploration of next-generation innovative therapies including cancer and autoimmune diseases. The product pipelines cover five major therapeutic areas including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. A total of four drugs ...
